About Lexeo Therapeutics, Inc. (LXEO)
Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy. The company also develops LX2022, a gene therapy candidate, which is in preclinical trial to deliver a functional TNNI3 gene to myocardial cells to treat a distinct form of hypertrophic cardiomyopathy. In addition, it is developing LX1001, an AAVrh10-based gene therapy candidate, which has completed phase 1/2 clinical trial for the treatment of APOE4-associated Alzheimer's disease. The company has license agreement with Cornell University to conduct of the Phase 1/2 clinical trial of LX1001, as well as support the development of LX1004 program; research collaboration agreement with Cornell University to conduct preclinical research to develop the licensed technology; and third license agreement which obtained certain rights for FA cardiomyopathy, including rights to current and future clinical data from an ongoing Cornell University investigator-initiated Phase 1A trial of a gene therapy candidate. The company was founded in 2017 and is headquartered in New York, New York.
Integration
Every way to get the Lexeo Therapeutics, Inc. (LXEO) logo
Same endpoint, same logo, resolved from whichever identifier your data already has. Pick one below to see the exact call -- SVG, PNG and WebP all come back from the same CDN-backed URL.
View full API docs<img src="https://api.logostream.dev/stocks/isin/US52886X1072?key=YOUR_API_KEY&variant=logo"
alt="Lexeo Therapeutics, Inc. (LXEO) logo"
width="64" height="64" /><a href="https://logostream.dev">Logos provided by logostream</a>Why Use Our Stock Logo API?
Fast Delivery
<100ms response time via global CDN
Enterprise-Ready
99.99% uptime SLA with GDPR compliance
Multiple Formats
SVG, PNG, WebP - scalable to any size
400k+ Logos
Stocks, ETFs, Crypto, Banks, and more
Where to Use Stock Logos
Trading Platforms
Real-time stock displays with instant logo loading
Portfolio Apps
Visualize holdings with recognizable brand logos
Financial Dashboards
Enhance market data with company branding
News & Research
Illustrate articles with accurate company logos
Frequently Asked Questions
The Lexeo Therapeutics, Inc. (LXEO) logo is a trademark of its respective owner. logostream is not affiliated with Lexeo Therapeutics, Inc. (LXEO) and provides this logo for identification purposes only. Logo usage is subject to the trademark holder's brand guidelines -- see our Terms of Service for the attribution requirements that apply to the Logo API.
Need Stock Logos for Your Application?
Access 380,000+ company logos via our simple REST API. Perfect for trading platforms, portfolio apps, and financial dashboards.